Gesundheitsforen Leipzig GmbH, Leipzig, Germany.
UCB Pharma, Monheim am Rhein, Germany.
Adv Ther. 2021 Jan;38(1):366-385. doi: 10.1007/s12325-020-01522-8. Epub 2020 Oct 30.
Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis (PSO) are chronic inflammatory diseases that have a substantial impact on patients' health. This retrospective database study aimed to assess the epidemiology, comorbidities, diagnosis and treatment patterns of RA, PsA and PSO in the German population.
Data were extracted from the Deutsche Forschungsdatenbank für Abrechnungsinformationen der Krankenversicherung database from 2012 to 2016 for patients aged ≥ 18 years holding full health coverage in the reporting year at least. Diagnoses were defined according to International Classification of Diseases (ICD)-10 codes. Reported outcomes included prevalence and incidence rates, pre-defined comorbidities, diagnosing and treating physicians, and treatment exposure. A subgroup analysis was performed for women of childbearing age (females aged 18-45 years).
The prevalence rates of RA, PsA and PSO in Germany were consistent over the study period; by 2016 they were 0.4%, 0.3% and 2.1%, respectively, and in women of childbearing age they were 0.2%, 0.2% and 1.5%, respectively. RA, PsA and PSO were predominantly observed among patients aged > 45 years. RA and PsA were more prevalent in women, while PSO had an approximately equal gender distribution. Depressive episodes were the most frequently reported comorbidity in 2016 (RA: 25.7%; PsA: 25.1%; PSO: 17.8%), and this was similar in women of childbearing age (RA: 20.5%; PsA: 23.4%; PSO: 16.3%). Approximately 50% of patients with RA and PsA and 6% of patients with PSO were receiving systemic treatment in 2016, of which methotrexate (RA: 38.4%; PsA: 30.2%; PSO: 2.2%) was most common. Biologic therapies were the least frequently used treatment options (RA: 28.9%; PsA: 20.9%; PSO: 1.8%).
This analysis provides key epidemiological information for patients with RA, PsA and PSO, including in women of childbearing age, in Germany and highlights common comorbidities and that patients were likely receiving insufficient treatment for these diagnoses.
类风湿关节炎(RA)、银屑病关节炎(PsA)和银屑病(PSO)是慢性炎症性疾病,它们对患者的健康有重大影响。这项回顾性数据库研究旨在评估德国人群中 RA、PsA 和 PSO 的流行病学、合并症、诊断和治疗模式。
从 2012 年至 2016 年,从德国研究数据银行(Deutsche Forschungsdatenbank für Abrechnungsinformationen der Krankenversicherung)数据库中提取了在报告年份至少拥有全面健康保险的年龄≥18 岁患者的数据。诊断根据国际疾病分类(ICD)第 10 版代码确定。报告的结果包括患病率和发病率、预先定义的合并症、诊断和治疗医生以及治疗暴露情况。对育龄妇女(18-45 岁女性)进行了亚组分析。
德国 RA、PsA 和 PSO 的患病率在整个研究期间保持一致;到 2016 年,分别为 0.4%、0.3%和 2.1%,而在育龄妇女中,分别为 0.2%、0.2%和 1.5%。RA、PsA 和 PSO 主要发生在年龄>45 岁的患者中。RA 和 PsA 在女性中更为常见,而 PSO 的性别分布大致相同。抑郁发作是 2016 年报告最多的合并症(RA:25.7%;PsA:25.1%;PSO:17.8%),在育龄妇女中也相似(RA:20.5%;PsA:23.4%;PSO:16.3%)。大约 50%的 RA 和 PsA 患者和 6%的 PSO 患者在 2016 年接受了系统治疗,其中甲氨蝶呤(RA:38.4%;PsA:30.2%;PSO:2.2%)最为常见。生物疗法是使用最少的治疗选择(RA:28.9%;PsA:20.9%;PSO:1.8%)。
这项分析为德国 RA、PsA 和 PSO 患者(包括育龄妇女)提供了关键的流行病学信息,并强调了常见的合并症,以及这些诊断的患者可能接受的治疗不足。